明熙资本领投，敏捷医疗完成数亿元B轮融资

Core Insights - Agile Medical Technology (Suzhou) Co., Ltd. has recently completed a multi-hundred million RMB Series B financing round, led by Mingxi Capital, with participation from Yuanhe Holdings, Licheng Investment, and Nantong Investment Management, along with continued investment from existing shareholders Qianji Capital and Yuanhe Origin [1][2] Group 1: Financing and Investment - The funds from this financing round will be primarily used for three key areas: deepening global commercialization efforts, accelerating the research and development iteration of surgical robot product lines, and further upgrading cutting-edge technology platforms [1] Group 2: Company Background and Product Development - Founded in 2020, Agile focuses on the surgical robot industry and has completed multiple rounds of financing prior to this [2] - The core product, AGIBOT® laparoscopic surgical robot, is expected to receive approval from the National Medical Products Administration (NMPA) by March 2025 and has already been applied in over a hundred clinical cases at leading institutions such as Nanjing University Medical School Affiliated Gulou Hospital and Zhengzhou University First Affiliated Hospital [2] - Agile has established a comprehensive capability loop from research and development to market, with a production base and user training center in Suzhou, capable of producing 100 systems and 20,000 surgical instruments annually, supporting professional user training for hundreds of individuals each year [2] - The company continues to strengthen its capabilities in technology research, pipeline development, industrial operations, and commercial expansion, forming a complete system covering "R&D - certification - mass production - commercialization" [2]